Live: Will Hims & Hers Rebound After Tonight’s Q2 Earnings?
Hims & Hers Health (HIMS) is set to report Q2 FY2026 results after the bell Aug 10. The article says Q1 gross margin fell to 65% and net loss was $92.11M on $608.10M revenue. For Q2, it cites guidance of $680M to $700M revenue and $35M to $55M adjusted EBITDA, with a Novo Nordisk Wegovy shipment figure of 125,000 units in six weeks.
How this was made
The 30-second read
Why it matters
Traders are likely to focus on whether Q2 revenue meets the $680M to $700M range, whether gross margin stabilizes versus the Q1 adjusted 70% level, and whether ARPU and subscriber growth reaccelerate alongside branded GLP-1 traction.
Market read
This is a pre-earnings setup for a single-stock catalyst, with concrete guidance ranges and specific operating metrics that can drive a large after-hours repricing.
What to watch
Eucalyptus timing is flagged as excluded from FY26 guidance; any update on closing mid-year could swing expectations for future revenue and profitability beyond the immediate Q2 numbers.
Background
The article sets up HIMS’s Q2 as a “reset quarter meets rebuild” after Q1 revenue growth but a sharp gross margin compression to 65% from 73%, tied to restructuring for GLP-1 strategy changes.
Ticker impact
Hims & Hers reports Q2 results tonight after the bell, with Q2 revenue guidance of $680M to $700M and margin repair focus after a Q1 gross margin drop to 65%.
High volatility expected into and after the after-hours Q2 release, with upside if gross margin stabilizes and revenue lands near the top end of guidance; downside if margin repair or subscriber growth disappoints.
The text provides specific Q2 and FY guidance ranges plus key operating metrics (gross margin, ARPU, international growth, Wegovy shipments) that directly map to the market’s core valuation debate for HIMS’s weight-loss strategy.
Market effects
Could influence sentiment around GLP-1-adjacent telehealth and branded compounding-to-branded transitions, especially for gross margin durability.
International revenue growth is highlighted (up 969% YoY to $78.19M), which may affect how traders price non-US expansion for similar models.
Novo Nordisk Wegovy shipment ramp is referenced, which can feed into broader expectations for demand and distribution capacity in GLP-1 supply chains.
Counterpoint
Even with strong Wegovy shipment counts, gross margin may remain structurally pressured by the compounded-to-branded shift and restructuring costs, limiting upside from revenue reacceleration alone.
Key entities
- companyHims & Hers Health
Subject of the article, scheduled to report Q2 FY2026 results after the bell, with guidance and operating metrics tied to its GLP-1 pivot.
- companyNovo Nordisk
Partner referenced for Wegovy shipments and ramp expectations that traders may use for read-through on HIMS’s weight-loss demand.
